Optimal composite measures for psoriatic arthritis

Jin-Xian Huang¹, Yung-Heng Lee^{2

3}, James Cheng-Chung Wei^{4

5

6}

Affiliations

¹ Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
² Department of senior services industry management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
³ Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
⁴ Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
⁵ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
⁶ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

Editorial

Jin-Xian Huang et al. Int J Rheum Dis. 2023 Oct.

. 2023 Oct;26(10):1897-1898.

doi: 10.1111/1756-185X.14829.

Jin-Xian Huang¹, Yung-Heng Lee^{2

3}, James Cheng-Chung Wei^{4

5

6}

¹ Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
² Department of senior services industry management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
³ Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
⁴ Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
⁵ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
⁶ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

No abstract available

Keywords: composite measure; psoriasis; psoriatic arthritis; treat-to-target.

References

1. Coates LC, FitzGerald O, Merola JF, et al. Group for Research and Assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018;70(3):345-355.
1. Orbai AM, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4):673-680.
1. Mulder MLM, van Hal TW, van den Hoogen FHJ, de Jong EMGJ, Vriezekolk JE, Wenink MH. Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. Rheumatology (Oxford). 2021;60(7):3165-3175.
1. Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology (Oxford). 2019;58(12):2251-2259.
1. Kasiem FR, Kok MR, Luime JJ, et al. Impact of psoriasis remains important in psoriatic arthritis patients with low musculoskeletal disease activity. Clin Exp Rheumatol. 2022;41(1):88-93.